Randomized Clinical Trial of BCG Vaccine in Patients with Convalescent COVID-19: Clinical Evolution, Adverse Events, and Humoral Immune Response

Overview

Journal J Intern Med

Specialty General Medicine

Date 2022 May 22

PMID 35599154

Authors

Mehrsa Jalalizadeh

Keini Buosi

Franciele A V Dionato

Luciana S B Dal Col

Cristiane F Giacomelli

Karen L Ferrari

Ana Carolina Pagliarone

Patricia A F Leme

Cristiane L Maia

Reza Yadollahvandmiandoab

Quoc-Dien Trinh

Kleber G Franchini

Marcio C Bajgelman

Leonardo O Reis

Affiliations

Soon will be listed here.

Abstract

Background: The Bacillus Calmette-Guérin (BCG) vaccine may confer cross-protection against viral diseases in adults. This study evaluated BCG vaccine cross-protection in adults with convalescent coronavirus disease 2019 (COVID-19).

Method: This was a multicenter, prospective, randomized, placebo-controlled, double-blind phase III study (ClinicalTrials.gov: NCT04369794).

Setting: University Community Health Center and Municipal Outpatient Center in South America.

Patients: a total of 378 adult patients with convalescent COVID-19 were included.

Intervention: single intradermal BCG vaccine (n = 183) and placebo (n = 195).

Measurements: the primary outcome was clinical evolution. Other outcomes included adverse events and humoral immune responses for up to 6 months.

Results: A significantly higher proportion of BCG patients with anosmia and ageusia recovered at the 6-week follow-up visit than placebo (anosmia: 83.1% vs. 68.7% healed, p = 0.043, number needed to treat [NNT] = 6.9; ageusia: 81.2% vs. 63.4% healed, p = 0.032, NNT = 5.6). BCG also prevented the appearance of ageusia in the following weeks: seven in 113 (6.2%) BCG recipients versus 19 in 126 (15.1%) placebos, p = 0.036, NNT = 11.2. BCG did not induce any severe or systemic adverse effects. The most common and expected adverse effects were local vaccine lesions, erythema (n = 152; 86.4%), and papules (n = 111; 63.1%). Anti-severe acute respiratory syndrome coronavirus 2 humoral response measured by N protein immunoglobulin G titer and seroneutralization by interacting with the angiotensin-converting enzyme 2 receptor suggest that the serum of BCG-injected patients may neutralize the virus at lower specificity; however, the results were not statistically significant.

Conclusion: BCG vaccine is safe and offers cross-protection against COVID-19 with potential humoral response modulation.

Limitations: No severely ill patients were included.

Citing Articles

The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?.

Pena-Bates C, Lascurain R, Ortiz-Navarrete V, Chavez-Galan L Heliyon. 2024; 10(18):e38085.

PMID: 39347386 PMC: 11437859. DOI: 10.1016/j.heliyon.2024.e38085.

Modulation of Human Macrophages by Plasma from COVID-19 Patients Following BCG Vaccination: BATTLE Trial.

Buosi K, Jalalizadeh M, Maia A, Morari J, Velloso L, Reis L Int J Gen Med. 2024; 17:3107-3117.

PMID: 39049828 PMC: 11268781. DOI: 10.2147/IJGM.S468047.

Host Genetic Background Influences BCG-Induced Antibodies Cross-Reactive to SARS-CoV-2 Spike Protein.

Specht A, Ginese M, Kurtz S, Elkins K, Specht H, Beamer G Vaccines (Basel). 2024; 12(3).

PMID: 38543876 PMC: 10975245. DOI: 10.3390/vaccines12030242.

The Influence of Cross-Reactive T Cells in COVID-19.

Eggenhuizen P, Ooi J Biomedicines. 2024; 12(3).

PMID: 38540178 PMC: 10967880. DOI: 10.3390/biomedicines12030564.

Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19.

Gong W, Du J J Korean Med Sci. 2023; 38(42):e343.

PMID: 37904656 PMC: 10615642. DOI: 10.3346/jkms.2023.38.e343.

References

Singh D, Parveen A, Yadav D . SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. Front Cell Infect Microbiol. 2021; 11:777212. PMC: 8713083. DOI: 10.3389/fcimb.2021.777212. View

Chen M, Shen W, Rowan N, Kulaga H, Hillel A, Ramanathan Jr M . Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020; 56(3). PMC: 7439429. DOI: 10.1183/13993003.01948-2020. View

Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J . The BCG Vaccine for COVID-19: First Verdict and Future Directions. Front Immunol. 2021; 12:632478. PMC: 7982405. DOI: 10.3389/fimmu.2021.632478. View

Meng X, Deng Y, Dai Z, Meng Z . COVID-19 and anosmia: A review based on up-to-date knowledge. Am J Otolaryngol. 2020; 41(5):102581. PMC: 7265845. DOI: 10.1016/j.amjoto.2020.102581. View

ONeill L, Netea M . BCG-induced trained immunity: can it offer protection against COVID-19?. Nat Rev Immunol. 2020; 20(6):335-337. PMC: 7212510. DOI: 10.1038/s41577-020-0337-y. View

Amirlak L, Haddad R, Hardy J, Khaled N, Chung M, Amirlak B . Effectiveness of booster BCG vaccination in preventing Covid-19 infection. Hum Vaccin Immunother. 2021; 17(11):3913-3915. PMC: 8425429. DOI: 10.1080/21645515.2021.1956228. View

Pettenati C, Ingersoll M . Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018; 15(10):615-625. DOI: 10.1038/s41585-018-0055-4. View

Fu W, Ho P, Liu C, Tzeng K, Nayeem N, Moore J . Reconcile the debate over protective effects of BCG vaccine against COVID-19. Sci Rep. 2021; 11(1):8356. PMC: 8052320. DOI: 10.1038/s41598-021-87731-9. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

10.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

11.

Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos D, van Crevel R . BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J Infect Dis. 2015; 212(12):1930-8. DOI: 10.1093/infdis/jiv332. View

12.

Bannister S, Sudbury E, Villanueva P, Perrett K, Curtis N . The safety of BCG revaccination: A systematic review. Vaccine. 2021; 39(20):2736-2745. DOI: 10.1016/j.vaccine.2020.08.016. View

13.

Arts R, Moorlag S, Novakovic B, Li Y, Wang S, Oosting M . BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018; 23(1):89-100.e5. DOI: 10.1016/j.chom.2017.12.010. View

14.

Noval Rivas M, Ebinger J, Wu M, Sun N, Braun J, Sobhani K . BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest. 2020; 131(2). PMC: 7810479. DOI: 10.1172/JCI145157. View

15.

Kumar N, Padmapriyadarsini C, Rajamanickam A, Marinaik S, Nancy A, Padmanaban S . Effect of BCG vaccination on proinflammatory responses in elderly individuals. Sci Adv. 2021; 7(32). PMC: 8336950. DOI: 10.1126/sciadv.abg7181. View

16.

Hojjat Jodaylami M, Djaileb A, Ricard P, Lavallee E, Cellier-Goetghebeur S, Parker M . Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. Sci Rep. 2021; 11(1):21601. PMC: 8575961. DOI: 10.1038/s41598-021-00844-z. View

17.

Pang N, Pang A, Chow V, Wang D . Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res. 2021; 8(1):47. PMC: 8405719. DOI: 10.1186/s40779-021-00342-3. View

18.

Jalalizadeh M, Buosi K, Dionato F, Col L, Giacomelli C, Ferrari K . Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response. J Intern Med. 2022; 292(4):654-666. PMC: 9347570. DOI: 10.1111/joim.13523. View

19.

Covian C, Fernandez-Fierro A, Retamal-Diaz A, Diaz F, Vasquez A, Lay M . BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. Front Immunol. 2019; 10:2806. PMC: 6896902. DOI: 10.3389/fimmu.2019.02806. View

20.

Gursel M, Gursel I . Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?. Allergy. 2020; 75(7):1815-1819. PMC: 7267226. DOI: 10.1111/all.14345. View